---
title: "Update: Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288756829.md"
description: "The US Supreme Court ruled against Amarin (AMRN) in a patent dispute regarding its drug Vascepa. The Court determined that Amarin failed to prove generic manufacturer Hikma Pharmaceuticals actively induced infringement of two patents after Hikka received approval for a 'skinny-label' generic version. Consequently, Amarin's complaint was dismissed. Amarin expressed disappointment and stated it is evaluating next steps while remaining committed to its mission."
datetime: "2026-06-04T17:25:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288756829.md)
  - [en](https://longbridge.com/en/news/288756829.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288756829.md)
---

# Update: Supreme Court Rules Against Amarin in 'Skinny Label' Patent Case

01:25 PM EDT, 06/04/2026 (MT Newswires) -- (Updates with Amarin's ( AMRN ) response to a request for comment in the penultimate paragraph.)

The US Supreme Court on Thursday ruled that Amarin ( AMRN ) failed to prove that a generic-drug manufacturer actively induced other companies to infringe upon two of its Vascepa patents after the generic maker received approval for a so-called "skinny-label" version of the drug.

Vascepa received Food and Drug Administration approval in 2012 for treating severe hypertriglyceridemia before receiving the FDA's go-ahead in 2019 for a second, more common use: lowering cardiovascular risk in hypertriglyceridemia patients who take statins, the so-called CV indication, for which it received two patents, the Supreme Court noted.

Hikma Pharmaceuticals received FDA approval for a generic icosapent ethyl skinny label in 2020 that carves out Vascepa's still-patented CV-indication method of use, the court noted.

"Amarin ( AMRN ) has failed to state a claim for active inducement in violation of \*271(b), so its complaint cannot withstand Hikma's motion to dismiss," the Supreme Court said.

"We are deeply disappointed by the Supreme Court's decision today and are evaluating our next steps," Amarin ( AMRN ) told MT Newswires in a statement. "Amarin ( AMRN ) remains fiercely dedicated to its primary mission: ensuring VASCEPA/VAZKEPA, a groundbreaking, innovative, and cost-effective therapy, reaches patients across the world who would benefit from this life-changing treatment."

Hikma didn't immediately reply to a request for comment from MT Newswires.

Price: 14.17, Change: -0.36, Percent Change: -2.48

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [AMRN.US](https://longbridge.com/en/quote/AMRN.US.md)
- [HIK.UK](https://longbridge.com/en/quote/HIK.UK.md)

## Related News & Research

- [US Supreme Court backs generic drugmaker in 'skinny label' patent case](https://longbridge.com/en/news/288735377.md)
- [Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma | HIK Stock News](https://longbridge.com/en/news/288777072.md)
- [Justice Sushil Sukumaran Nair appointed as Court of Appeal judge](https://longbridge.com/en/news/289552957.md)
- [The Supreme Court Backed the FCC and Here Is Why It Matters](https://longbridge.com/en/news/288972242.md)
- [Amarin Shareholders Reject Dilution, Governance Proposals at AGM](https://longbridge.com/en/news/286548345.md)